References
- Al-Marrawi MY, Rini BI, Harshman GA, et al (2011). The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts.). J Clin Oncol, 29, 4555. https://doi.org/10.1200/JCO.2011.36.7490
- AJCC Cancer Staging Manual, Seventh Edition (2010). published by Springer New York, Inc.
- Cohen RB, Oudard S (2012). Antiangiogenic therapy for advanced renal cell carcinoma: management of treatmentrelated toxicities. Invest New Drugs, 30, 2066-79. https://doi.org/10.1007/s10637-012-9796-8
- Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5. https://doi.org/10.7314/APJCP.2013.14.3.2101
- Donskov F (2013). Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Sem Cancer Biol, 23, 200-7. https://doi.org/10.1016/j.semcancer.2013.02.001
- Ferlay J, Shin HR, Bray F, et al (2010) International Agency for Research on Cancer. The GLOBOCON Project. http://globocan.iarc.fr.
- Hanninen LE, Kirchner H, Atzpodien J (1996). Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol, 155, 19-25. https://doi.org/10.1016/S0022-5347(01)66527-3
- Heng DY, Xie W, Regan MM, et al (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factortargeted agents: results from a large, multicenter study. J Clin Oncol, 27, 5794-9. https://doi.org/10.1200/JCO.2008.21.4809
- Kapoor AK, Hotte SJ (2007). Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Can Urol Assoc J, 1, 28-33.
- Mathew A, Devesa SS, Fraumeni JF, et al (2002). Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev, 11, 171-8. https://doi.org/10.1097/00008469-200204000-00010
- Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24. https://doi.org/10.1056/NEJMoa065044
- Motzer RJ, Michaelson MD, Redman BG, et al (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, 16-24. https://doi.org/10.1200/JCO.2005.02.2574
- Motzer RJ, Hutson TE, Olsen MR, et al (2011). Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continupus dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT trial. J Clin Oncol, 29, 308. https://doi.org/10.1200/JCO.2010.32.6082
- Ohno Y, Nakashima J, Ohori M, et al (2010). Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol, 184, 873-8. https://doi.org/10.1016/j.juro.2010.05.028
- Ohno Y, Nakashima J, Ohori M, et al (2012). Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol, 187, 411-7. https://doi.org/10.1016/j.juro.2011.10.026
- Porta C, Procopio G, Carteni G, et al (2011). Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int, 108, 250-7. https://doi.org/10.1111/j.1464-410X.2011.10186.x
- Sternberg CN, Davis ID, Mardiak J, et al (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 28, 1061-8. https://doi.org/10.1200/JCO.2009.23.9764
- Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42. https://doi.org/10.7314/APJCP.2013.14.9.5237
- Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31. https://doi.org/10.7314/APJCP.2013.14.9.5527
- Yang JC, Sherry RM, Steinberg SM, et al (2003). Randomized study of high-dose and low-dose interleukin-2 in patients withmetastatic renal cancer. J Clin Oncol, 21, 3127-32. https://doi.org/10.1200/JCO.2003.02.122
- Willett CG, Boucher Y, di Tomaso E, et al (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10, 145. https://doi.org/10.1038/nm988
Cited by
- Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab? vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4781
- Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5687
- Neutrophil to lymphocyte ratio is an independent prognostic factor in patients with recurrent or metastatic head and neck squamous cell cancer vol.3, pp.4, 2015, https://doi.org/10.3892/mco.2015.557
- Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy vol.21, pp.2, 2016, https://doi.org/10.1007/s10147-015-0894-4
- Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio vol.39, pp.4, 2016, https://doi.org/10.1002/hed.24681
- Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis vol.67, pp.5, 2018, https://doi.org/10.1007/s00262-018-2126-z